series-c
Stage
About
Storm Therapeutics develops small molecule inhibitors targeting RNA modifying enzymes, focusing on their lead drug STC-15, a first-in-class METTL3 inhibitor in clinical trials for treating sarcoma.
Explore Storm Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.